In this study, the development of clinical synkinesis after facial nerve paralysis (FP) and its relationship to electrophysiological findings were investigated. Thirty-four patients who were examined within the first 5 days after onset of FP and who could also be followed up for at least 4 months were included in the study. Electrophysiological investigations consisted of: (1) recording of the direct responses by facial nerve stimulation at the stylomastoid fossa; (2) recording of the ‘synkinetic spread’ of the supraorbital nerve reflex to the lower facial muscles; (3) recording of the ‘lateral spread responses’ by stimulating the mandible and zygomatic branches of the facial nerve. Clinical synkinesis developed in 14 of 18 patients (78%) with a direct response ratio (DRr) of less than 40%. Among the 16 patients with a DRr of 40% or more, synkinesis was observed in 3 cases (18.7%) only. The DRr provided reliable information concerning the development of synkinesis. Forty percent seemed to be a reasonable limit to distinguish the high-risk group for the development of clinical synkinesis.

Keywords:
Facial palsy, Synkinesis, Electroneurography, Ephaptic transmission
1.
Moran CJ, Neely JG: Patterns of facial nerve synkinesis. Laryngoscope 1996;106:1491–1496.
2.
Baker RS, Stava MW, Nelson KR, May PJ, Huffman MD, Porter JD: Aberrant reinnervation of facial musculature in a subhuman primate: A correlative analysis of eyelid kinematics, muscle synkinesis, and motoneuron localization. Neurology 1994;44:2165–2173.
3.
Nielsen VK: Pathophysiology of hemifacial spasm. I. Ephaptic transmission and ectopic excitation. Neurology 1984;34:418–426.
4.
Nielsen VK: Pathophysiology of hemifacial spasm. II. Lateral spread of the supraorbital nerve reflex. Neurology 1984;34:427–431.
5.
Kimura J, Rodnitzky RL, Okawara SH: Electrophysiologic analysis of aberrant regeneration after facial nerve paralysis. Neurology 1975;25:989–993.
6.
Öge AE, Yazici J, Boyacıyan A, Tanyeri S, Çelik M, Konyalıoğlu R, Baslo A: Magnetic stimulation in hemifacial spasm and post-facial palsy synkinesis. Muscle Nerve 1993;16:1154–1160.
7.
Çelik M, Forta H: Electrophysiological investigations and prognosis in idiopathic facial palsy. Electromyogr Clin Neurophysiol 1997;37:311–315.
8.
May M, Klein SR, Taylor FH, Pittsburgh PA: Idiopathic (Bell’s) facial palsy: Natural history defies steroid or surgical treatment. Laryngoscope 1985;95:406–409.
9.
Neuwirth RK, Burian M, Nekahm D, Gestottner W: Optimizing of electroneurography of the facial nerve. Otorhinolaryngology 1990;52:360–367.
10.
Maeyama H, Aoyagi M, Tojima H, Inamura H, Kohsyu H, Koike Y: Electrophysiological study on the pathology of synkinesis after facial nerve paralysis. Acta Otolaryngol (Stockh) 1994;suppl 551:161–164.
11.
Yamamoto E, Nishimura H, Hirono Y: Occurrence of sequelae in Bell’s Palsy. Acta Otolaryngol (Stockh) 1988;suppl 446:93–96.
12.
Cossu G, Valls-Sole J, Valldeoriola F, Munoz E, Benitez P, Aguilar F: Reflex excitability of facial motoneurons at onset of muscle reinnervation after facial nerve palsy. Muscle Nerve 1999;22:614–620.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.